Dendreon (NASDAQ:DNDN) -- a biotech company that receives a lot of attention on Fool.com and is hotly debated as a stock -- has recently announced that it will be making an aggressive direct-to-consumer marketing push. In the following video, Motley Fool health care analyst David Williamson explains what this means for investors and what he is looking for in a national ad campaign.

David Williamson has no position in any stocks mentioned. Follow him on Twitter @MotleyDavid. Max Macaluso has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.